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Abstract
Aims/hypothesis The aim of the present study was to
investigate whether predetermined contact frequency with the
studyteamandendpoint insulindose areassociatedwithstudy
outcomes in basal insulin initiation trials in type 2 diabetes.
Methods A systematic Medline search was performed.
Using data from the selected studies, contact frequency
was plotted against HbA1c reduction and endpoint insulin
dose. The importance of face-to-face vs telephone contact
was also analysed. Insulin dose was plotted against HbA1c
reduction, hypoglycaemia rate and weight gain. To inves-
tigate non-specific study effects, the relationship between
contact frequency and HbA1c was also assessed in
dipeptidyl peptidase-4 (DPP-4) inhibitor trials.
Results The reduction in HbA1c was highly correlated with
contact frequency and endpoint insulin dose (r
2=0.751,
p<0.001 and r
2=0.433, p=0.008, respectively). However,
after adjusting for contact frequency, the relationship between
insulin dose and HbA1c reduction was no longer significant
(p=0.270). The frequency of both clinical and telephone
contacts were independent predictors of HbA1c improvement
(p=0.010 and p<0.001, respectively). We found no dose–
response relationship between end-of-study insulin dose and
hypoglycaemia or weight gain. In DPP-4 inhibitor studies,
contact frequency was not positively associated with HbA1c.
Conclusions/interpretation The frequency of contact with
the study team is highly correlated with the improvement in
HbA1c achieved in basal insulin initiation trials in type 2
diabetic patients. This has important implications for trial
design and interpretation, as well as for clinical care.
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Introduction
In type 2 diabetes basal insulin preparations are advocated for
the initiation of insulin therapy [1]. Insulin initiation using
insulin detemir (NN304) [B29Lys(ε-tetradecanoyl),desB30
human insulin] or insulin glargine (A21Gly,B31Arg,B32Arg
human insulin) has been examined in a number of Phase 3
and 4 clinical studies [2–8], comparing either analogue with
NPH insulin or with each other [6] for their ability to
decrease HbA1c levels. However, in addition to the merits of
the insulin preparation under investigation, factors related to
the design of the trials may affect this and other study
endpoints. Therefore, we explored whether frequency of
contact with the study team as per study protocol and
endpoint insulin dose are associated with study outcomes in
randomised controlled trials (RCTs) comparing insulin
initiation with one basal insulin vs another in insulin-naive
participants with type 2 diabetes.
Methods
Medline was searched using the terms ‘detemir’, ‘glargine’,
‘neutral protamine hagedorn’, ‘NPH’, ‘neutral protamine
lispro’, ‘NPL’, ‘type 2 diabetes’, ‘non-insulin dependent
diabetes mellitus’ and ‘NIDDM’. In order to take the
current more stringent glycaemic goals and the relatively
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search was limited to studies published between April
1999 and April 2009. All English-language RCTs with a
duration ≥24 weeks comparing insulin initiation with a
basal insulin vs another basal insulin in insulin-naive type 2
diabetic participants were included. Studies investigating
combination therapy with rapid-acting insulin and those
that had differences across treatment arms in additional
glucose-lowering interventions (e.g. oral agents), titration
algorithms and/or contact frequency were excluded.
The search yielded 417 papers, including 112 RCTs, of
which ten met our criteria [2–11]. Using these, associations
between the frequency of contact as per protocol and the
study outcomes reduction in HbA1c and endpoint daily
insulin dose were explored by plotting the contact frequency
(clinical and telephone contacts combined and standardised
to the number of contacts per year) against the two outcome
measures. To examine the relative importance of clinical vs
telephone contact, we standardised both to the number of
contacts per year and performed a multivariable linear
regression analysis. Similarly, endpoint insulin dose, related
to the study design factors titration frequency and titration
target, was plotted against the study outcomes HbA1c
reduction, hypoglycaemia rate and weight gain. For all
associations, we performed weighted least squares regression
using treatment group size as the weight variable.
Of the ten included studies, two were excluded from all
analyses as they did not report contact frequency, endpoint
insulin dose as U kg
−1 day
−1 or endpoint weight [2, 11].
One more study did not mention the frequency of contact
[9]. Three more studies did not report insulin dose as
Uk g
−1 day
−1 but for two this could be calculated [3, 4]. For
another three studies the change in HbA1c was calculated
[5, 7, 8]. Concerning hypoglycaemia, the studies used
variable definitions. We used event rates rather than
numbers of participants affected to account for the effect
of study duration on hypoglycaemia frequency. We defined
hypoglycaemia as an event confirmed by a low glucose
measurement, as this definition maximised the number of
studies that could be included in the analysis [4–7, 9]. All
in all, 15 treatment groups were analysed for the associa-
tions between contact frequency and HbA1c, dose and
HbA1c, and dose and weight gain; 13 were analysed for the
association between contact frequency and dose, and ten for
the association between dose and hypoglycaemia.
In addition to the efficacy of the study insulin and certain
features of the study design, improvements in HbA1c during
trial participation may result from non-specific study effects
[12, 13]. To investigate these non-specific study benefits,
we also determined the relationship between contact
frequency and HbA1c reduction in studies examining the
initiation of dipeptidyl peptidase-4 (DPP-4) inhibitors. Both
study populations chose to start a new intervention in the
setting of a clinical trial, so presumably all were equally
motivated to improve their diabetes management. However,
in contrast with the continuous dose titration during the
insulin trials, fixed dosages were used throughout the
DPP-4 studies. We included the trials that were recently
meta-analysed in a Cochrane systematic review and that
compared DPP-4 inhibitor monotherapy with placebo or a
single oral glucose-lowering agent [14]. After exclusion of
one study because of lack of contact frequency data, we
analysed 14 studies comprising 29 DPP-4 inhibitor treat-
ment groups.
Results
Figure 1a shows that the improvement in HbA1c achieved
in studies of basal insulin initiation in patients with type 2
diabetes was highly correlated with the predetermined
frequency of contact with the study team (r
2=0.751,
p<0.001). Multivariable analysis of the standardised numb-
ers of clinical visits and telephone contacts showed a strong
association with HbA1c reduction (adjusted r
2 value 0.754).
Both frequencies were independent predictors of HbA1c
improvement (p=0.010 and p<0.001 for clinical and
telephone contacts, respectively). The regression equation
was: HbA1c reduction=0.282+(0.033×number of clinical
contacts per year)+(0.055×number of telephone contacts
per year). In the DPP-4 studies, however, higher contact
frequency was not, and, if anything, negatively associated
with greater improvement in glycaemic control (r
2=0.233,
standardised β=−0.483, p=0.008) (Fig. 1f).
In the insulin trials, we also found significant relationships
between contact frequency and insulin dose at study endpoint
(r
2=0.366,p=0.028) (Fig. 1b), and between endpoint insulin
dose and HbA1c reduction (r
2=0.433, p=0.008) (Fig. 1c).
The effect of increasing insulin doses on the occurrence of
hypoglycaemia was not apparent in insulin-naive patients
(r
2=0.011, p=0.774), and we found no evidence for a dose–
response relationship between insulin dose and weight gain
(r
2=0.076, p=0.320) (Fig. 1d, e). Finally, to determine
whether contact frequency and insulin dose were also
independently associated with improvement in glycaemic
control, we performed a multivariable regression analysis.
The adjusted r
2 value of this model was 0.718, and while
contact frequency remained an independent predictor of
HbA1c reduction (p=0.003), insulin dose did not (p=0.270).
Discussion
Our main finding was that, while there were significant
dose–response relationships between the predetermined
frequency of contact and endpoint insulin dose and the
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investigating basal insulin initiation in type 2 diabetic
patients, only contact frequency was an independent
predictor of HbA1c reduction. The frequency of both
clinical visits and telephone contacts showed a significant
relationship with HbA1c improvement, but a higher fre-
quency of telephone contact may be particularly beneficial.
In studies examining the start of DPP-4 inhibitors we did
not find a positive association between contact frequency
and HbA1c improvement.
Assuming that the non-specific study effects of the
insulin and DPP-4 trials were comparable, the lack of a
logical association between contact frequency and HbA1c
improvement in the latter studies suggests that the benefit
of frequent patient contact found in the insulin trials is
primarily related to the frequency of insulin dose titration.
This is supported not only by Fig. 1b, which shows a
significant relationship between contact frequency and
insulin doses used at study endpoint, but also by the
multivariable analysis of the frequencies of clinical and
telephone contacts. The higher β coefficient for telephone
contacts suggests that these may be more beneficial than
clinical visits, presumably due to their focus on dose
titration (compared with the performance of many study-
related procedures during clinical visits).
However, it cannot be ruled out that the non-specific study
benefits did indeed differ between the two types of trials. In
type 1 diabetes, the improvement in glycaemic control after
trial participation itselfwas found tobe mediated byincreased
self-monitoring of blood glucose (SMBG) and a more active
coping style [13]. In contrast with the insulin initiation trials,
SMBG was not performed in the DPP-4 studies. Addition-
ally, it is possible that patients failing on oral therapy and
requiring insulin are more ‘ready for change’ and more
motivated to do well than those (merely) starting on
another tablet. However, regardless of whether the benefit
of regular patient contact is primarily related to titration
frequency or to non-specific study effects, our analyses
demonstrate that predetermined contact frequency is a
major determinant of the HbA1c improvement achieved in
insulin initiation trials. In addition to the obvious conse-
quences for the design and interpretation of clinical trials
comparing different insulin preparations, our findings have
important implications for patient care, in as far as providing
frequent contact after starting insulin therapy may be very
effective in improving glycaemic control.
Fig. 1 Relationships between (a) the frequency of contact with the
study team as per study protocol and mean reduction in HbA1c level
(15 treatment groups, r
2=0.751, standardised β=0.866, p<0.001), and
(b) the frequency of contact and mean end-of-study daily insulin dose
(13 treatment groups, r
2=0.366, standardised β=0.605, p=0.028).
Relationships between mean endpoint daily insulin dose and (c) mean
reduction in HbA1c level (15 treatment groups, r
2=0.433, standardised
β=0.658, p=0.008), (d) rate of hypoglycaemia confirmed by a low
glucose measurement per patient-year (ten treatment groups,
r
2=0.011, standardised β=−0.104, p=0.774) and (e) mean weight
gain (15 treatment groups, r
2=0.076, standardised β=−0.276,
p=0.320). RCTs comparing insulin initiation with a basal insulin vs
another basal insulin in insulin-naive participants with type 2 diabetes
were analysed. f Relationship between the predetermined frequency of
contact and mean reduction in HbA1c level in clinical studies
investigating initiation of DPP-4 inhibitor treatment (29 treatment
groups, r
2=0.233, standardised β=−0.483, p=0.008). The size of the
symbols reflects treatment group size
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hypoglycaemia event rate, but this may reflect the low a priori
risk of hypoglycaemia of the study populations. These type 2
diabeticparticipantshad juststarted insulintreatment,so were
presumably protected against hypoglycaemia by residual
endogenous insulin secretion. An alternative possible expla-
nation for the observed lack of a relationship is that
participants on higher daily doses after titration have similar
ratesofhypoglycaemiatothoseinwhomtitrationisstoppedat
lower insulin doses. In this case, the graph could suggest that
perceived risk of hypoglycaemia is the signal to stop insulin
dose titration. The lack of association between insulin dose
and weight gain suggests that the weight increase commonly
seen after initiation of insulin therapy is related to reductions
inglucosuriaand/orincreased energyintake,rather thantothe
number of insulin injections or the daily insulin dose [15].
In conclusion, the frequency of contact with the study
team is highly correlated with the improvement in glycae-
mic control achieved after basal insulin initiation in type 2
diabetes. Our analyses indicate that when comparing the
outcomes of different clinical trials, their design should also
be considered. Our findings also have implications for trial
design and patient care. Frequent contact and dose titration
may facilitate successful insulin initiation.
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